Eikon Therapeutics, Inc. EIKN
—
7.92
(0.37)
(4.46%)
as of 25 Sep
- Market cap
- $449.0M
- P/E
- 0.0×
Follow EIKN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
9.89 | 11.75 | 6.34 | — |
+2 more quarters Free account |
Net Debt/EBITDA |
6.02 | 6.23 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
0.73 | 1.08 | 0.00 | 0.31 | |
Capex/Depreciation |
(0.05) | (0.05) | (1.93) | (3.44) | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(1.20) | (2.67) | 0.00 | (19.12) | |
Cash per Share |
9.82 | 15.21 | 0.00 | 0.00 | |
Shareholders Equity per Share |
8.62 | 16.34 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
8.62 | 16.34 | 0.00 | 0.00 | |
Free Cash Flow |
(65.21) | (90.06) | (235.26) | (54.45) | |
Working Capital |
491.68 | 484.44 | 293.91 | — | |
Capital Expenditures |
(0.25) | (0.26) | (46.74) | (21.72) | |
Net Current Asset Value |
233.91 | 229.35 | (1,124.85) | 0.00 | |
| Other line items | |||||
Quick Ratio |
9.61 | 11.37 | 6.12 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(1.20) | (2.66) | 0.00 | (11.49) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (7.62) | |
Average Assets |
389.79 | 671.03 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | — | 0.00% |
Columns are period end dates